However, to the best of our knowledge, there is no study evaluating the effect of systemic therapy in high-risk infants for early intervention on atopic march. This is a narrative review that addresses the latest knowledge of moderate to severe AD in children with a focus...
Atopic dermatitis (AD) is a prevalent, chronic, inflammatory skin condition, affecting approximately 25% of children and 10% of adults. Persons with moderate-to-severe AD often experience a high disease burden that has a significant impact on quality of life. Recent years have seen a substantial...
This randomized clinical trial evaluates the efficacy and safety of cendakimab compared with placebo in patients with moderate to severe atopic dermatitis.
This was an observational and retrospective multicentre study conducted on adolescents and adults diagnosed with moderate-to-severe atopic dermatitis (AD) and treated with upadacitinib. Disease severity was measured by Eczema Area and Severity Index (EASI), validated investigator global assessment for ...
Outcome measures used in this study have been validated for atopic dermatitis and are recommended by HOME21. The mean baseline values for EASI, pruritus NRS, POEM, and DLQI are presented in Table2, and correspond to severe disease. Table 2 Change in efficacy outcomes after 16, 32 and 52 we...
Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively. Upadacitinib was effective in treating patients with moderate to severe atopic dermatitis (AD) after more than 1 year of continuous treat...
The management of moderate to severe atopic dermatitis in adults with topical fluti- casone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140:1115-21.Van Der Meer JB, Glazenburg EJ, Mulder PG, et al.: The management of moderate to severe atopic ...
The Eczema Area and Severity Index (EASI) was 8.1, Severity Scoring of Atopic Dermatitis (SCORAD) was 66.4,Dermatology Life Quality Index (DLQI) was 18,Pruritus Numerical Rating Scale (NRS) was 10, which showed a severe atopic dermatitis.We referred to the guidelines for the treatment of PN...
Dr. Boguniewicz, when you think about moderate to severe atopic dermatitis, which is a group that really suffers… If you’re on the milder side, some of the basic things like good moisturization or topical corticosteroids, they can give a lot of relief, but as you get more function...
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD)